Publication date: Nov 12, 2019 Although relapsing-remitting multiple sclerosis (RRMS) has a chronic course, little information is known about the comparison between the disease-modifying therapies (DMT) for long-term outcomes. We ... Read more

Publication date: Jun 15, 2020 Relapses of multiple sclerosis (MS) are the clinical manifestations of inflammatory events involving eloquent anatomical structures within the central nervous system. Relapses are associated with ... Read more

Publication date: Jun 01, 2020 We reviewed present topics on neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein (MOG)-antibody-associated disease (MOGAD). The number of NMOSD-related publications have increased year ... Read more

Publication date: May 26, 2020 The purpose of this review is to discuss the interaction between aging, progressive disease course, disability worsening, and treatment strategies in multiple sclerosis (MS). The ... Read more

Publication date: May 20, 2020 Circulating microRNAs have emerged as novel multiple sclerosis (MS) biomarkers. To assess the association between candidate miRs expression in serum samples of patients with MS ... Read more

Publication date: Apr 26, 2020 In relapsing-remitting multiple sclerosis (RRMS), no evidence of disease activity-3 (NEDA-3) is defined as the absence of: (1) relapses; (2) disability progression; (3) MRI activity ... Read more

Publication date: May 05, 2020 No randomized controlled clinical trial of therapeutic plasma exchanges (TPE) has yet been performed for moderate-to-severe relapses of multiple sclerosis (MS). To compare TPE to ... Read more